SecBot SecBot
424B5 ·Filed Apr 13, 2026

RVMDW

Revolution Medicines, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed7mo ago SEC0001193125-26-152978
Notable filing: 424B5
Actionable Insight ▼ Bearish

Investors should anticipate near-term dilution from the stock offering and potential future dilution from the convertible notes. The concurrent nature of these capital raises suggests the company is strengthening its balance sheet but at the cost of shareholder value. Monitor the use of proceeds and whether the note offering is completed.

DirectionBearish
Confidencehigh
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines is conducting a $750 million common stock offering and a concurrent $250 million convertible note offering. The stock offering will dilute existing shareholders and increase capital, while the convertible notes add leverage and potential future dilution upon conversion.

Key Facts

  • Revolution Medicines is offering $750 million of common stock
  • Concurrently offering $250 million aggregate principal amount of convertible senior notes due 2033
  • The two offerings are not contingent on each other's completion
  • Stock offering will result in immediate dilution to new investors
  • Convertible notes could lead to future dilution upon conversion

Financial Impact

The company will receive approximately $750 million from the stock offering and $250 million from the convertible notes, less underwriting discounts and expenses

dilutiondebtcash

Risk Factors

  • Significant dilution to existing shareholders from the stock offering
  • Future dilution potential from convertible notes
  • Increased leverage from the debt offering
  • Market may react negatively to the dilutive capital raise

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-152978
Document: 0001193125-26-152978-index-headers.html0001193125-26-152978
Document: 0001193125-26-152978-index.html0001193125-26-152978
Document: 0001193125-26-152978.txt0001193125-26-152978

Track record

8 reports on RVMDW

Performance horizon

0 of 3 bullish or bearish reports moved the stock their way by T+60. Best: 0.00% at T+1 after the Apr 15, 2026 report. 0 of 3 went positive at some point.

Filters
  1. Apr 17, 202630w ago 8-K Bearish 8/10 Entry $1.88 to $9.07 ▼ −382.45% −375.67% vs SPY
  2. Apr 16, 202630w ago 8-K Neutral 6/10 Entry $1.88 to $8.98 ▲ +377.66% +371.52% vs SPY
  3. Apr 15, 202630w ago 424B5 Neutral 6/10 Entry $1.88 to $8.96 ▲ +376.60% +369.55% vs SPY
  4. Apr 15, 202630w ago 424B5 Bearish 7/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  5. Apr 15, 202630w ago 144 Bearish 6/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
  6. Apr 13, 202631w ago 424B5 Bearish 7/10 Viewing Entry $1.88 No price data
  7. Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
  8. Apr 13, 202631w ago 8-K Bullish 8/10 Entry $1.88 No price data
Showing 8 of 8

US Market Status

Market Closed · Opens in 8h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026